Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? European Urology 2024, 86: 366-368. PMID: 38879371, DOI: 10.1016/j.eururo.2024.05.027.Peer-Reviewed Original ResearchBacillus Calmette-GuerinBCG-unresponsiveMP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT?
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. MP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT? Journal Of Urology 2024, 211: e242. DOI: 10.1097/01.ju.0001008640.01272.9d.08.Peer-Reviewed Original ResearchBCG-unresponsiveONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Annapureddy D, Taylor J, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Facundo D, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. ONCOLOGIC OUTCOMES OF GEMCITABINE-DOCETAXEL COMBINATION INTRAVESICAL BLADDER SPARING THERAPY COMPARED TO UPFRONT RADICAL CYSTECTOMY IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER. Urologic Oncology Seminars And Original Investigations 2024, 42: s52-s53. DOI: 10.1016/j.urolonc.2024.01.160.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsive NMIBCMultinational cohort of patientsUpfront RCCancer-specific survivalInvasive bladder cancerRadical cystectomyOncological outcomesCohort of patientsAdequate BCGBCG therapyBCG-unresponsiveSalvage therapySpecific survivalBladder cancerMultinational cohortBCG-unresponsive NMIBC patientsAdequate BCG therapyBladder sparing therapyCombination intravesical therapyMaintenance BCG therapyNode positivity rateCompare oncologic outcomesNATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT
Taylor J, Annapureddy D, Howard J, Woldu S, Lotan Y, Tan W, Kamat A, McElree I, Packiam V, O'Donnell M, Davaro F, Li R, Yim K, Preston M, Harrington S, Dyer E, Raman J, Black A, Black P, Kanabur P, Lerner S, Roumiguié M, Steinberg G, Huang W. NATURAL HISTORY OF BLADDER-SPARING THERAPY IN PATIENTS WITH BCG-UNRESPONSIVE DISEASE; RESULTS FROM A LARGE MULTI-CENTER COHORT. Urologic Oncology Seminars And Original Investigations 2024, 42: s49. DOI: 10.1016/j.urolonc.2024.01.152.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBCG-unresponsive NMIBCBladder-sparing therapyBCG-unresponsive diseaseBCG-unresponsiveRate of cystectomyCohort of patientsOncological outcomesRadical cystectomyBladder cancer deathAdequate BCGBCG therapyOncological riskCancer deathRetrospective multi-center cohortInternational cohort of patientsAdequate BCG therapyAlternative intravesical agentsIntravesical mitomycin CMaintenance BCG therapyNatural historyUpfront radical cystectomyInferior oncologic outcomesMulti-center cohort of patientsUpper tract disease